Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | RiMO-301 |
Trade Name | |
Synonyms | RiMO301|RiMO 301 |
Drug Descriptions |
RiMO-301 is a nanoparticle-based metal-organic framework that may enhance radiosensivity and activity of immunotherapy (PMID: 32607433, J Clin Oncol 2023 41:16_suppl, 2527). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C148280 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Nivolumab + RiMO-301 | Nivolumab RiMO-301 | 0 | 1 |
Pembrolizumab + Radiotherapy + RiMO-301 | Pembrolizumab Radiotherapy RiMO-301 | 0 | 0 |
Pembrolizumab + RiMO-301 | Pembrolizumab RiMO-301 | 0 | 1 |
Radiotherapy + RiMO-301 | Radiotherapy RiMO-301 | 0 | 0 |
RiMO-301 | RiMO-301 | 0 | 1 |